CleftGeneDB-Search

Gene: SFN

Basic information

Tag	Content
Uniprot ID	P31947; Q6FH30; Q6FH51; Q96DH0;
Entrez ID	2810
Genbank protein ID	CAA40623.1; AAH23552.1; AAH00329.1; CAG46703.1; AAC52029.1; AAH02995.1; AAH00995.1; AAC52030.1; CAG46724.1; AAH01550.1; AAA59546.1;
Genbank nucleotide ID	NM_006142.3
Ensembl protein ID	ENSP00000340989
Ensembl nucleotide ID	ENSG00000175793
Gene name	14-3-3 protein sigma
Gene symbol	SFN
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. When bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway. May also regulate MDM2 autoubiquitination and degradation and thereby activate p53/TP53.
Sequence	MERASLIQKA KLAEQAERYE DMAAFMKGAV EKGEELSCEE RNLLSVAYKN VVGGQRAAWR 60 VLSSIEQKSN EEGSEEKGPE VREYREKVET ELQGVCDTVL GLLDSHLIKE AGDAESRVFY 120 LKMKGDYYRY LAEVATGDDK KRIIDSARSA YQEAMDISKK EMPPTNPIRL GLALNFSVFH 180 YEIANSPEEA ISLAKTTFDE AMADLHTLSE DSYKDSTLIM QLLRDNLTLW TADNAGEEGG 240 EAPQEPQS 248

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1YWT
1YZ5
3IQJ
3IQU
3IQV
3LW1
3MHR
3O8I
3P1N
3P1O
3P1P
3P1Q
3P1R
3P1S
3SMK
3SML
3SMM
3SMN
3SMO
3SP5
3SPR
3T0L
3T0M
3U9X
3UX0
4DAT
4DAU
4DHM
4DHN
4DHO
4DHP
4DHQ
4DHR
4DHS
4DHT
4DHU
4FL5
4FR3
4IEA
4JC3
4JDD
4QLI
4Y32
4Y3B
4Y5I
5BTV
5HF3
5LTW
5LU1
5LU2
5MHC
5MOC
5MXO
5MY9
5MYC
5N5R
5N5T
5N5W
5N75
5OEG
5OEH
5OK9
5OKF
5OM0
5OMA
6FAU
6FAV
6FAW
6FBB
6FBW
6FBY
6FCP
6FI4
6FI5
6G6X
6G8I
6G8J
6G8K
6G8L
6G8P
6G8Q
6GHP
6HHP
6HKB
6HKF
6HMT
6HMU
6HN2
6QDR
6QDS
6QDT
6QDU
6QZR
6QZS
6TLF
6TLG
6TM7
6Y1J
3IQU
3T0M
5MY9

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Developmental stage	Species	Evidence	Details
1:1 ortholog	SFN	528453	Q0VC36			Bos taurus	Prediction	More>>
1:1 ortholog	SFN	487351	F1PQ93			Canis lupus familiaris	Prediction	More>>
1:1 ortholog	SFN	102190744	A0A452DME8			Capra hircus	Prediction	More>>
1:1 ortholog	SFN	100057082	F7CIM1			Equus caballus	Prediction	More>>
1:1 ortholog	SFN	2810	P31947			Homo sapiens	Prediction	More>>
1:1 ortholog	Sfn	55948	O70456	CPO	E14.5	Mus musculus	Publication	More>>
1:1 ortholog	SFN	737412	H2RC87			Pan troglodytes	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs927409697	p.Glu2Gln	missense variant	-	NC_000001.11:g.26863216G>C	gnomAD
rs1425894772	p.Arg3Lys	missense variant	-	NC_000001.11:g.26863220G>A	gnomAD
rs1286955504	p.Ala4Thr	missense variant	-	NC_000001.11:g.26863222G>A	TOPMed
rs568265886	p.Ala4Val	missense variant	-	NC_000001.11:g.26863223C>T	1000Genomes,ExAC,gnomAD
rs1444841133	p.Ser5Asn	missense variant	-	NC_000001.11:g.26863226G>A	TOPMed
NCI-TCGA novel	p.Gln8Ter	stop gained	-	NC_000001.11:g.26863234C>T	NCI-TCGA
rs1214429299	p.Gln8Arg	missense variant	-	NC_000001.11:g.26863235A>G	TOPMed
rs765149882	p.Lys9Glu	missense variant	-	NC_000001.11:g.26863237A>G	ExAC,gnomAD
rs1269201151	p.Lys11Thr	missense variant	-	NC_000001.11:g.26863244A>C	TOPMed
rs750413218	p.Lys11Glu	missense variant	-	NC_000001.11:g.26863243A>G	ExAC,gnomAD
NCI-TCGA novel	p.Ala16Val	missense variant	-	NC_000001.11:g.26863259C>T	NCI-TCGA
rs768668023	p.Arg18His	missense variant	-	NC_000001.11:g.26863265G>A	ExAC,TOPMed,gnomAD
rs1213057759	p.Tyr19Cys	missense variant	-	NC_000001.11:g.26863268A>G	gnomAD
rs1284171025	p.Tyr19Ter	stop gained	-	NC_000001.11:g.26863269T>G	gnomAD
rs754674489	p.Glu20Lys	missense variant	-	NC_000001.11:g.26863270G>A	ExAC,TOPMed,gnomAD
rs1216736508	p.Asp21Tyr	missense variant	-	NC_000001.11:g.26863273G>T	gnomAD
rs1244262729	p.Met22Thr	missense variant	-	NC_000001.11:g.26863277T>C	gnomAD
rs780504299	p.Ala23Thr	missense variant	-	NC_000001.11:g.26863279G>A	ExAC,TOPMed,gnomAD
rs780504299	p.Ala23Ser	missense variant	-	NC_000001.11:g.26863279G>T	ExAC,TOPMed,gnomAD
rs1399070532	p.Ala24Val	missense variant	-	NC_000001.11:g.26863283C>T	TOPMed
rs747687239	p.Met26Arg	missense variant	-	NC_000001.11:g.26863289T>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Lys27Glu	missense variant	-	NC_000001.11:g.26863291A>G	NCI-TCGA
rs755742043	p.Ala29Thr	missense variant	-	NC_000001.11:g.26863297G>A	ExAC,gnomAD
rs753163340	p.Val30Met	missense variant	-	NC_000001.11:g.26863300G>A	TOPMed,gnomAD
rs952539380	p.Glu31Asp	missense variant	-	NC_000001.11:g.26863305G>T	TOPMed,gnomAD
COSM1296236	p.Glu31Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.26863305G>C	NCI-TCGA Cosmic
rs368467494	p.Glu31Gln	missense variant	-	NC_000001.11:g.26863303G>C	ESP,ExAC,TOPMed,gnomAD
rs187432842	p.Lys32Glu	missense variant	-	NC_000001.11:g.26863306A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
COSM4031046	p.Lys32Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.26863308G>T	NCI-TCGA Cosmic
rs1244045492	p.Glu34Lys	missense variant	-	NC_000001.11:g.26863312G>A	gnomAD
rs772341113	p.Glu35Lys	missense variant	-	NC_000001.11:g.26863315G>A	ExAC,gnomAD
rs775634377	p.Glu35Gly	missense variant	-	NC_000001.11:g.26863316A>G	ExAC,gnomAD
rs1237836535	p.Leu36Phe	missense variant	-	NC_000001.11:g.26863318C>T	gnomAD
rs760725031	p.Cys38Arg	missense variant	-	NC_000001.11:g.26863324T>C	ExAC,gnomAD
rs1281832393	p.Cys38Phe	missense variant	-	NC_000001.11:g.26863325G>T	TOPMed
rs1224602073	p.Glu39Lys	missense variant	-	NC_000001.11:g.26863327G>A	gnomAD
rs764202539	p.Glu39Gly	missense variant	-	NC_000001.11:g.26863328A>G	ExAC,gnomAD
NCI-TCGA novel	p.Leu44Ile	missense variant	-	NC_000001.11:g.26863342C>A	NCI-TCGA
rs773098369	p.Leu44His	missense variant	-	NC_000001.11:g.26863343T>A	ExAC,gnomAD
rs762900135	p.Ser45Leu	missense variant	-	NC_000001.11:g.26863346C>T	ExAC,TOPMed,gnomAD
rs77608477	p.Val46Ala	missense variant	-	NC_000001.11:g.26863349T>C	ExAC,TOPMed,gnomAD
rs77608477	p.Val46Glu	missense variant	-	NC_000001.11:g.26863349T>A	ExAC,TOPMed,gnomAD
rs754798184	p.Tyr48Cys	missense variant	-	NC_000001.11:g.26863355A>G	ExAC,TOPMed,gnomAD
rs767182909	p.Lys49Arg	missense variant	-	NC_000001.11:g.26863358A>G	ExAC,gnomAD
rs1438240956	p.Asn50Lys	missense variant	-	NC_000001.11:g.26863362C>A	TOPMed
rs1379217298	p.Val51Leu	missense variant	-	NC_000001.11:g.26863363G>C	gnomAD
rs1470145884	p.Val51Glu	missense variant	-	NC_000001.11:g.26863364T>A	gnomAD
rs752340232	p.Gly54Cys	missense variant	-	NC_000001.11:g.26863372G>T	ExAC,gnomAD
rs1411127009	p.Gln55Lys	missense variant	-	NC_000001.11:g.26863375C>A	gnomAD
rs1404569381	p.Gln55His	missense variant	-	NC_000001.11:g.26863377G>T	gnomAD
rs1230924301	p.Ala57Pro	missense variant	-	NC_000001.11:g.26863381G>C	TOPMed
NCI-TCGA novel	p.Trp59Cys	missense variant	-	NC_000001.11:g.26863389G>C	NCI-TCGA
rs777455603	p.Ser63Pro	missense variant	-	NC_000001.11:g.26863399T>C	ExAC,gnomAD
rs1469586278	p.Ser64Gly	missense variant	-	NC_000001.11:g.26863402A>G	TOPMed
rs1444565685	p.Glu66Lys	missense variant	-	NC_000001.11:g.26863408G>A	gnomAD
rs1335263115	p.Gln67Lys	missense variant	-	NC_000001.11:g.26863411C>A	gnomAD
rs1281524630	p.Ser69Asn	missense variant	-	NC_000001.11:g.26863418G>A	gnomAD
rs1281524630	p.Ser69Asn	missense variant	-	NC_000001.11:g.26863418G>A	NCI-TCGA
rs757850238	p.Asn70Lys	missense variant	-	NC_000001.11:g.26863422C>A	ExAC,TOPMed,gnomAD
COSM3984941	p.Glu71Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.26863424A>G	NCI-TCGA Cosmic
rs1232876831	p.Glu71Lys	missense variant	-	NC_000001.11:g.26863423G>A	gnomAD
rs779078184	p.Gly73Asp	missense variant	-	NC_000001.11:g.26863430G>A	ExAC,gnomAD
rs772373713	p.Glu76Gln	missense variant	-	NC_000001.11:g.26863438G>C	ExAC,TOPMed,gnomAD
rs780294710	p.Gly78Arg	missense variant	-	NC_000001.11:g.26863444G>C	ExAC,gnomAD
rs768674631	p.Glu80Lys	missense variant	-	NC_000001.11:g.26863450G>A	ExAC,TOPMed,gnomAD
rs768674631	p.Glu80Ter	stop gained	-	NC_000001.11:g.26863450G>T	ExAC,TOPMed,gnomAD
rs1331324158	p.Val81Met	missense variant	-	NC_000001.11:g.26863453G>A	TOPMed
rs923826779	p.Arg82His	missense variant	-	NC_000001.11:g.26863457G>A	TOPMed,gnomAD
rs1316263162	p.Arg85Gln	missense variant	-	NC_000001.11:g.26863466G>A	TOPMed
rs935169241	p.Arg85Gly	missense variant	-	NC_000001.11:g.26863465C>G	TOPMed
rs1169884128	p.Glu86Lys	missense variant	-	NC_000001.11:g.26863468G>A	gnomAD
rs1169884128	p.Glu86Lys	missense variant	-	NC_000001.11:g.26863468G>A	NCI-TCGA
rs770898389	p.Gln93Lys	missense variant	-	NC_000001.11:g.26863489C>A	ExAC,gnomAD
rs1338746196	p.Val95Met	missense variant	-	NC_000001.11:g.26863495G>A	gnomAD
rs532069878	p.Asp97Asn	missense variant	-	NC_000001.11:g.26863501G>A	NCI-TCGA,NCI-TCGA Cosmic
rs532069878	p.Asp97Asn	missense variant	-	NC_000001.11:g.26863501G>A	1000Genomes,ExAC,gnomAD
rs138537988	p.Val99Met	missense variant	-	NC_000001.11:g.26863507G>A	ESP,gnomAD
rs1251263499	p.Gly101Asp	missense variant	-	NC_000001.11:g.26863514G>A	gnomAD
rs1435874533	p.Asp104His	missense variant	-	NC_000001.11:g.26863522G>C	gnomAD
rs760421743	p.Ser105Arg	missense variant	-	NC_000001.11:g.26863527C>A	ExAC,gnomAD
rs371597532	p.His106Asn	missense variant	-	NC_000001.11:g.26863528C>A	ESP,TOPMed,gnomAD
rs1476737385	p.Lys109Thr	missense variant	-	NC_000001.11:g.26863538A>C	gnomAD
rs150754661	p.Glu110Lys	missense variant	-	NC_000001.11:g.26863540G>A	ESP,ExAC,TOPMed,gnomAD
rs1184208913	p.Asp113Gly	missense variant	-	NC_000001.11:g.26863550A>G	TOPMed
rs756892225	p.Asp113Asn	missense variant	-	NC_000001.11:g.26863549G>A	ExAC,gnomAD
rs756892225	p.Asp113Asn	missense variant	-	NC_000001.11:g.26863549G>A	NCI-TCGA,NCI-TCGA Cosmic
rs375934637	p.Glu115Lys	missense variant	-	NC_000001.11:g.26863555G>A	ESP,TOPMed,gnomAD
rs779455161	p.Glu115Asp	missense variant	-	NC_000001.11:g.26863557G>C	ExAC,gnomAD
rs552239770	p.Ser116Thr	missense variant	-	NC_000001.11:g.26863559G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs552239770	p.Ser116Asn	missense variant	-	NC_000001.11:g.26863559G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs747176654	p.Val118Ile	missense variant	-	NC_000001.11:g.26863564G>A	ExAC,gnomAD
rs747176654	p.Val118Phe	missense variant	-	NC_000001.11:g.26863564G>T	ExAC,gnomAD
rs1367921010	p.Leu121Val	missense variant	-	NC_000001.11:g.26863573C>G	TOPMed
COSM3804826	p.Met123Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.26863581G>T	NCI-TCGA Cosmic
rs781461664	p.Asp126Asn	missense variant	-	NC_000001.11:g.26863588G>A	ExAC,gnomAD
rs368924622	p.Arg129His	missense variant	-	NC_000001.11:g.26863598G>A	ESP,ExAC,TOPMed,gnomAD
rs368924622	p.Arg129Pro	missense variant	-	NC_000001.11:g.26863598G>C	ESP,ExAC,TOPMed,gnomAD
rs1230335721	p.Arg129Gly	missense variant	-	NC_000001.11:g.26863597C>G	TOPMed,gnomAD
rs1230335721	p.Arg129Cys	missense variant	-	NC_000001.11:g.26863597C>T	TOPMed,gnomAD
rs1465427902	p.Ala132Asp	missense variant	-	NC_000001.11:g.26863607C>A	TOPMed
rs201166719	p.Ala132Ser	missense variant	-	NC_000001.11:g.26863606G>T	1000Genomes,TOPMed
COSM136105	p.Glu133Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.26863609G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Glu133Ter	stop gained	-	NC_000001.11:g.26863609G>T	NCI-TCGA
rs1282050143	p.Glu133Gly	missense variant	-	NC_000001.11:g.26863610A>G	TOPMed,gnomAD
rs1487132670	p.Ala135Thr	missense variant	-	NC_000001.11:g.26863615G>A	gnomAD
rs1430020795	p.Gly137Ser	missense variant	-	NC_000001.11:g.26863621G>A	TOPMed,gnomAD
rs1181338202	p.Asp139Gly	missense variant	-	NC_000001.11:g.26863628A>G	TOPMed,gnomAD
rs1174388676	p.Asp139Glu	missense variant	-	NC_000001.11:g.26863629C>A	gnomAD
rs778492845	p.Asp139Asn	missense variant	-	NC_000001.11:g.26863627G>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Lys140Asn	missense variant	-	NC_000001.11:g.26863632G>T	NCI-TCGA
rs1418170142	p.Arg142Cys	missense variant	-	NC_000001.11:g.26863636C>T	gnomAD
rs1317136406	p.Ile144Val	missense variant	-	NC_000001.11:g.26863642A>G	TOPMed
rs1384213747	p.Ala147Val	missense variant	-	NC_000001.11:g.26863652C>T	gnomAD
rs1384124244	p.Arg148Gly	missense variant	-	NC_000001.11:g.26863654C>G	gnomAD
rs78707984	p.Ser149Leu	missense variant	-	NC_000001.11:g.26863658C>T	ESP,ExAC,TOPMed,gnomAD
rs78707984	p.Ser149Leu	missense variant	-	NC_000001.11:g.26863658C>T	NCI-TCGA
rs753596278	p.Met155Val	missense variant	-	NC_000001.11:g.26863675A>G	ExAC,gnomAD
rs761357509	p.Ile157Met	missense variant	-	NC_000001.11:g.26863683C>G	ExAC,gnomAD
NCI-TCGA novel	p.Glu161Lys	missense variant	-	NC_000001.11:g.26863693G>A	NCI-TCGA
rs149812347	p.Glu161Asp	missense variant	-	NC_000001.11:g.26863695G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs149812347	p.Glu161Asp	missense variant	-	NC_000001.11:g.26863695G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1252121721	p.Met162Thr	missense variant	-	NC_000001.11:g.26863697T>C	gnomAD
rs1255573669	p.Pro163Thr	missense variant	-	NC_000001.11:g.26863699C>A	TOPMed
rs1468889117	p.Pro163Leu	missense variant	-	NC_000001.11:g.26863700C>T	gnomAD
rs77755255	p.Thr165Ser	missense variant	-	NC_000001.11:g.26863705A>T	ExAC,TOPMed,gnomAD
rs75914997	p.Pro167Leu	missense variant	-	NC_000001.11:g.26863712C>T	ExAC,TOPMed,gnomAD
rs75914997	p.Pro167Arg	missense variant	-	NC_000001.11:g.26863712C>G	ExAC,TOPMed,gnomAD
rs202094692	p.Arg169Cys	missense variant	-	NC_000001.11:g.26863717C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs202094692	p.Arg169Gly	missense variant	-	NC_000001.11:g.26863717C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1364564256	p.Gly171Ser	missense variant	-	NC_000001.11:g.26863723G>A	gnomAD
rs775830382	p.Gly171Val	missense variant	-	NC_000001.11:g.26863724G>T	ExAC,TOPMed,gnomAD
rs775830382	p.Gly171Ala	missense variant	-	NC_000001.11:g.26863724G>C	ExAC,TOPMed,gnomAD
COSM1341444	p.Leu172Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.26863727T>A	NCI-TCGA Cosmic
rs745760220	p.Phe176Val	missense variant	-	NC_000001.11:g.26863738T>G	ExAC
rs775634605	p.Val178Gly	missense variant	-	NC_000001.11:g.26863745T>G	ExAC,gnomAD
rs771907479	p.Val178Ile	missense variant	-	NC_000001.11:g.26863744G>A	ExAC,gnomAD
rs746785587	p.Phe179Tyr	missense variant	-	NC_000001.11:g.26863748T>A	ExAC,TOPMed,gnomAD
rs1450787410	p.Glu182Lys	missense variant	-	NC_000001.11:g.26863756G>A	TOPMed,gnomAD
rs1318405070	p.Glu182Gly	missense variant	-	NC_000001.11:g.26863757A>G	gnomAD
rs1242119597	p.Glu182Asp	missense variant	-	NC_000001.11:g.26863758G>C	gnomAD
rs776384378	p.Ala184Thr	missense variant	-	NC_000001.11:g.26863762G>A	ExAC,TOPMed,gnomAD
rs776384378	p.Ala184Ser	missense variant	-	NC_000001.11:g.26863762G>T	ExAC,TOPMed,gnomAD
rs965426042	p.Asn185Ser	missense variant	-	NC_000001.11:g.26863766A>G	TOPMed
NCI-TCGA novel	p.Ser186Arg	missense variant	-	NC_000001.11:g.26863770C>G	NCI-TCGA
rs761394832	p.Glu188Lys	missense variant	-	NC_000001.11:g.26863774G>A	ExAC,gnomAD
rs764746422	p.Glu188Val	missense variant	-	NC_000001.11:g.26863775A>T	ExAC,gnomAD
rs568387371	p.Ile191Val	missense variant	-	NC_000001.11:g.26863783A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs762595295	p.Ala194Thr	missense variant	-	NC_000001.11:g.26863792G>A	ExAC,gnomAD
rs1232444148	p.Thr196Ser	missense variant	-	NC_000001.11:g.26863799C>G	TOPMed
rs766860880	p.Thr197Ala	missense variant	-	NC_000001.11:g.26863801A>G	ExAC,gnomAD
rs1383657566	p.Asp199Val	missense variant	-	NC_000001.11:g.26863808A>T	TOPMed,gnomAD
rs1186073578	p.Asp199His	missense variant	-	NC_000001.11:g.26863807G>C	gnomAD
rs1486267642	p.Glu200Lys	missense variant	-	NC_000001.11:g.26863810G>A	TOPMed
rs1417669561	p.Ala203Thr	missense variant	-	NC_000001.11:g.26863819G>A	gnomAD
COSM680162	p.Asp204Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.26863822G>A	NCI-TCGA Cosmic
rs1206948680	p.Leu205Val	missense variant	-	NC_000001.11:g.26863825C>G	TOPMed
rs1462232360	p.His206Tyr	missense variant	-	NC_000001.11:g.26863828C>T	TOPMed,gnomAD
rs1488099786	p.Thr207Ala	missense variant	-	NC_000001.11:g.26863831A>G	TOPMed
rs756298691	p.Ser209Arg	missense variant	-	NC_000001.11:g.26863839C>A	ExAC,gnomAD
rs752911202	p.Ser209Arg	missense variant	-	NC_000001.11:g.26863837A>C	ExAC,gnomAD
rs777841410	p.Glu210Lys	missense variant	-	NC_000001.11:g.26863840G>A	ExAC,gnomAD
NCI-TCGA novel	p.Glu210Ter	stop gained	-	NC_000001.11:g.26863840G>T	NCI-TCGA
rs1285899313	p.Asp215Asn	missense variant	-	NC_000001.11:g.26863855G>A	gnomAD
rs1393982955	p.Asp215Glu	missense variant	-	NC_000001.11:g.26863857C>G	gnomAD
rs757413612	p.Ser216Gly	missense variant	-	NC_000001.11:g.26863858A>G	ExAC,gnomAD
rs1431911960	p.Thr217Ile	missense variant	-	NC_000001.11:g.26863862C>T	TOPMed
rs1030897040	p.Leu218Val	missense variant	-	NC_000001.11:g.26863864C>G	TOPMed,gnomAD
rs1030897040	p.Leu218Phe	missense variant	-	NC_000001.11:g.26863864C>T	TOPMed,gnomAD
rs1364859549	p.Ile219Met	missense variant	-	NC_000001.11:g.26863869C>G	TOPMed
NCI-TCGA novel	p.Met220SerPheSerTerUnk	frameshift	-	NC_000001.11:g.26863869_26863872CATG>-	NCI-TCGA
rs746975829	p.Gln221Arg	missense variant	-	NC_000001.11:g.26863874A>G	ExAC,gnomAD
rs1306901123	p.Leu222Met	missense variant	-	NC_000001.11:g.26863876C>A	gnomAD
rs776580736	p.Arg224Gln	missense variant	-	NC_000001.11:g.26863883G>A	ExAC,gnomAD
NCI-TCGA novel	p.Asp225Asn	missense variant	-	NC_000001.11:g.26863885G>A	NCI-TCGA
NCI-TCGA novel	p.Thr228Ala	missense variant	-	NC_000001.11:g.26863894A>G	NCI-TCGA
rs1454934500	p.Thr228Ile	missense variant	-	NC_000001.11:g.26863895C>T	TOPMed
rs745925685	p.Thr231Arg	missense variant	-	NC_000001.11:g.26863904C>G	gnomAD
rs769330167	p.Asp233Glu	missense variant	-	NC_000001.11:g.26863911C>A	ExAC,gnomAD
rs1417773375	p.Ala235Thr	missense variant	-	NC_000001.11:g.26863915G>A	gnomAD
rs369790436	p.Gly236Arg	missense variant	-	NC_000001.11:g.26863918G>A	ESP,ExAC,TOPMed,gnomAD
rs765911499	p.Glu238Asp	missense variant	-	NC_000001.11:g.26863926G>C	ExAC,TOPMed,gnomAD
rs376687682	p.Gly239Val	missense variant	-	NC_000001.11:g.26863928G>T	ESP,ExAC,TOPMed,gnomAD
rs915043131	p.Gly239Arg	missense variant	-	NC_000001.11:g.26863927G>A	TOPMed
rs1416223429	p.Gly240Ser	missense variant	-	NC_000001.11:g.26863930G>A	gnomAD
rs753008567	p.Glu241Lys	missense variant	-	NC_000001.11:g.26863933G>A	NCI-TCGA,NCI-TCGA Cosmic
rs753008567	p.Glu241Lys	missense variant	-	NC_000001.11:g.26863933G>A	ExAC,gnomAD
rs1215149660	p.Pro243Ala	missense variant	-	NC_000001.11:g.26863939C>G	gnomAD
rs1297564385	p.Gln244His	missense variant	-	NC_000001.11:g.26863944G>T	gnomAD
rs968862899	p.Gln244Ter	stop gained	-	NC_000001.11:g.26863942C>T	TOPMed
COSM4400725	p.Glu245Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.26863945G>A	NCI-TCGA Cosmic
rs1208755675	p.Glu245Asp	missense variant	-	NC_000001.11:g.26863947G>T	gnomAD
rs761167385	p.Glu245Gln	missense variant	-	NC_000001.11:g.26863945G>C	ExAC,gnomAD
rs191803556	p.Pro246Leu	missense variant	-	NC_000001.11:g.26863949C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1242069424	p.Gln247Arg	missense variant	-	NC_000001.11:g.26863952A>G	TOPMed,gnomAD
NCI-TCGA novel	p.Gln247His	missense variant	-	NC_000001.11:g.26863953G>C	NCI-TCGA
rs757373679	p.Ter249Ser	stop lost	-	NC_000001.11:g.26863958G>C	ExAC,TOPMed,gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	BEFREE;LHGDN
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007133	Carcinoma, Papillary	disease	LHGDN
C0007137	Squamous cell carcinoma	disease	BEFREE;CTD_human;LHGDN
C0009404	Colorectal Neoplasms	group	LHGDN
C0010606	Adenoid Cystic Carcinoma	disease	LHGDN
C0014859	Esophageal Neoplasms	group	BEFREE;CTD_human
C0022548	Keloid	phenotype	CTD_human
C0024121	Lung Neoplasms	group	BEFREE
C0024232	Lymphatic Metastasis	disease	BEFREE;CTD_human
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0026640	Mouth Neoplasms	group	CTD_human;LHGDN
C0026764	Multiple Myeloma	disease	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE;LHGDN
C0030193	Pain	phenotype	BEFREE
C0030297	Pancreatic Neoplasm	disease	LHGDN
C0033578	Prostatic Neoplasms	group	LHGDN
C0040137	Thyroid Nodule	disease	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE;CTD_human
C0152018	Esophageal carcinoma	disease	BEFREE
C0153381	Malignant neoplasm of mouth	disease	CTD_human
C0175754	Agenesis of corpus callosum	disease	BEFREE
C0206694	Mucoepidermoid Carcinoma	disease	BEFREE
C0206698	Cholangiocarcinoma	disease	LHGDN
C0220668	Congenital contractural arachnodactyly	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0278488	Carcinoma breast stage IV	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE;CTD_human
C0279751	Adenoid cystic carcinoma of salivary gland	disease	BEFREE
C0282160	Aplasia Cutis Congenita	disease	BEFREE
C0334276	Adenocarcinoma in Situ	phenotype	BEFREE
C0346153	Breast Cancer, Familial	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0406709	Hay-Wells syndrome	disease	BEFREE
C0546837	Malignant neoplasm of esophagus	disease	BEFREE;CTD_human
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0878500	Intraepithelial Neoplasia	disease	BEFREE
C0919267	ovarian neoplasm	disease	LHGDN
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1458155	Mammary Neoplasms	group	LHGDN
C2239176	Liver carcinoma	disease	BEFREE;CTD_human
C2931822	Nasopharyngeal carcinoma	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0005515	protein binding	IPI
GO:0008426	protein kinase C inhibitor activity	TAS
GO:0019901	protein kinase binding	IEA
GO:0019904	protein domain specific binding	IEA
GO:0042802	identical protein binding	IPI
GO:0045296	cadherin binding	HDA
GO:0051219	phosphoprotein binding	IEA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000079	regulation of cyclin-dependent protein serine/threonine kinase activity	IEA
GO:0001836	release of cytochrome c from mitochondria	IDA
GO:0003334	keratinocyte development	IEA
GO:0006469	negative regulation of protein kinase activity	TAS
GO:0006977	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	TAS
GO:0007165	signal transduction	TAS
GO:0008630	intrinsic apoptotic signaling pathway in response to DNA damage	IDA
GO:0010482	regulation of epidermal cell division	ISS
GO:0010839	negative regulation of keratinocyte proliferation	IEA
GO:0030307	positive regulation of cell growth	IEA
GO:0031424	keratinization	IEA
GO:0043154	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	IDA
GO:0045606	positive regulation of epidermal cell differentiation	ISS
GO:0046827	positive regulation of protein export from nucleus	IEA
GO:0061024	membrane organization	TAS
GO:0061436	establishment of skin barrier	ISS
GO:0071901	negative regulation of protein serine/threonine kinase activity	IEA
GO:1900740	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	TAS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005615	extracellular space	TAS
GO:0005634	nucleus	IEA
GO:0005739	mitochondrion	IEA
GO:0005829	cytosol	IDA
GO:0005829	cytosol	TAS
GO:0070062	extracellular exosome	HDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-109581	Apoptosis	TAS
R-HSA-109606	Intrinsic Pathway for Apoptosis	TAS
R-HSA-111447	Activation of BAD and translocation to mitochondria	TAS
R-HSA-114452	Activation of BH3-only proteins	TAS
R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-1640170	Cell Cycle	TAS
R-HSA-194315	Signaling by Rho GTPases	TAS
R-HSA-195258	RHO GTPase Effectors	TAS
R-HSA-199991	Membrane Trafficking	IEA
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-3700989	Transcriptional Regulation by TP53	TAS
R-HSA-5357801	Programmed Cell Death	TAS
R-HSA-5625740	RHO GTPases activate PKNs	TAS
R-HSA-5628897	TP53 Regulates Metabolic Genes	TAS
R-HSA-5653656	Vesicle-mediated transport	IEA
R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	TAS
R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	TAS
R-HSA-69473	G2/M DNA damage checkpoint	TAS
R-HSA-69481	G2/M Checkpoints	TAS
R-HSA-69620	Cell Cycle Checkpoints	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	TAS
R-HSA-9614085	FOXO-mediated transcription	TAS
R-HSA-9614399	Regulation of localization of FOXO transcription factors	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
D020001	1-Butanol	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of SFN protein	26558463
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in decreased expression of SFN mRNA	28801915
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in increased expression of SFN mRNA	30723492
C532162	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of SFN mRNA	20453058
C029497	2,3-bis(3'-hydroxybenzyl)butyrolactone	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SFN mRNA	19167446
C063002	2,3-dimethoxy-1,4-naphthoquinone	2,3-dimethoxy-1,4-naphthoquinone results in increased expression of SFN mRNA	17547211
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	[3,4,5,3',4'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylnitrosamine] results in increased expression of SFN protein	23457121
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of SFN mRNA	19167416; 22213190;
C023035	3,4,5,3',4'-pentachlorobiphenyl	[3,4,5,3',4'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylnitrosamine] results in increased expression of SFN protein	23457121
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in increased expression of SFN mRNA	21527772
D000082	Acetaminophen	Acetaminophen results in decreased expression of SFN mRNA	21420995; 29067470;
D000082	Acetaminophen	Acetaminophen results in increased expression of SFN mRNA	22230336
C109238	acyline	acyline results in increased expression of SFN mRNA	17510436
C106812	adefovir dipivoxil	adefovir dipivoxil results in increased expression of SFN mRNA	25596134
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of SFN protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of SFN mRNA	21527772; 21632981; 22100608;
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of SFN mRNA	24449571
D001151	Arsenic	Arsenic results in increased expression of SFN mRNA	19945496
D000077237	Arsenic Trioxide	SFN protein results in decreased susceptibility to Arsenic Trioxide	20707922
D001379	Azathioprine	Azathioprine results in increased expression of SFN mRNA	22623647
C030935	benz(a)anthracene	benz(a)anthracene results in decreased expression of SFN mRNA	26377693
D001548	Benzalkonium Compounds	Benzalkonium Compounds results in increased expression of SFN mRNA	30171875
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of SFN mRNA	20106945; 21632981; 22316170; 25690898; 26238291;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased mutagenesis of SFN gene	25435355
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of SFN mRNA	19770486
C022921	benzo(k)fluoranthene	benzo(k)fluoranthene results in decreased expression of SFN mRNA	26377693
D019324	beta-Naphthoflavone	beta-Naphthoflavone results in increased expression of SFN mRNA	19737606
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased methylation of SFN promoter	30616060
C543008	bis(4-hydroxyphenyl)sulfone	[bis(4-hydroxyphenyl)sulfone co-treated with Tretinoin] results in decreased expression of SFN mRNA	30951980
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of SFN mRNA	30951980
C006780	bisphenol A	bisphenol A affects the expression of SFN mRNA	30903817
C006780	bisphenol A	[bisphenol A co-treated with Tretinoin] results in decreased expression of SFN mRNA	30951980
C006780	bisphenol A	bisphenol A results in decreased methylation of SFN promoter	27312807
C006780	bisphenol A	bisphenol A results in decreased expression of SFN mRNA	25181051
C000611646	bisphenol F	[bisphenol F co-treated with Tretinoin] results in decreased expression of SFN mRNA	30951980
C000611646	bisphenol F	bisphenol F results in increased expression of SFN mRNA	30951980
D000069286	Bortezomib	Bortezomib results in increased expression of SFN mRNA	20977926
D000069286	Bortezomib	[Irinotecan co-treated with Bortezomib] results in decreased expression of SFN protein	16373703
D003994	Bucladesine	[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of SFN mRNA	22534328
D003994	Bucladesine	[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein	22534328
C026105	butylidenephthalide	butylidenephthalide results in increased expression of SFN protein	23770345
C584509	C646 compound	C646 compound results in decreased expression of SFN mRNA	26191083
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of SFN mRNA	12160620; 25596134;
D019256	Cadmium Chloride	[Cadmium Chloride co-treated with diallyl disulfide] results in decreased expression of SFN mRNA	31077537
D002117	Calcitriol	Calcitriol results in increased expression of SFN mRNA	26485663
C459604	candoxin	candoxin results in decreased expression of SFN mRNA	16309724
D002220	Carbamazepine	Carbamazepine affects the expression of SFN mRNA	25979313
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of SFN mRNA	30723492
D002699	Chlorambucil	Chlorambucil results in increased expression of SFN mRNA	18092340
C004656	chloroacetaldehyde	chloroacetaldehyde results in increased expression of SFN mRNA	25596134
C100187	chloropicrin	chloropicrin results in decreased expression of SFN mRNA	26352163
D002737	Chloroprene	Chloroprene results in increased expression of SFN mRNA	23125180
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SFN mRNA	20938992
C043561	chrysin	chrysin results in increased expression of SFN mRNA	18331776
C043561	chrysin	chrysin results in increased expression of SFN protein	18331776
D000077404	Cidofovir	Cidofovir results in increased expression of SFN mRNA	25596134
D002945	Cisplatin	Cisplatin affects the expression of SFN mRNA	25450742
D002945	Cisplatin	Cisplatin promotes the reaction [jinfukang results in increased expression of SFN mRNA]	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of SFN protein	21924258
D002945	Cisplatin	Cisplatin results in increased expression of SFN mRNA	21532991; 25596134; 27392435;
D002945	Cisplatin	jinfukang promotes the reaction [Cisplatin results in increased expression of SFN mRNA]	27392435
D002945	Cisplatin	SFN protein affects the susceptibility to Cisplatin	26894857
D002945	Cisplatin	SFN protein affects the susceptibility to [Fluorouracil co-treated with Cisplatin]	15999354
D004002	Clodronic Acid	Clodronic Acid results in increased expression of SFN mRNA	25596134
D003300	Copper	[ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of SFN mRNA	15467011
D003300	Copper	Copper results in increased expression of SFN mRNA	22465980
D019327	Copper Sulfate	Copper Sulfate results in increased expression of SFN mRNA	19549813
D003375	Coumestrol	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SFN mRNA	19167446
D003375	Coumestrol	Coumestrol results in increased expression of SFN mRNA	19167446
D003520	Cyclophosphamide	Cyclophosphamide results in increased expression of SFN mRNA	21527772
D016572	Cyclosporine	Cyclosporine results in increased expression of SFN mRNA	20106945; 25562108; 25596134; 27989131; 30008028;
D003561	Cytarabine	SFN protein results in decreased susceptibility to Cytarabine	25189999
D003609	Dactinomycin	Dactinomycin results in increased expression of SFN mRNA	21527772
D000077209	Decitabine	Decitabine results in increased expression of SFN protein	22534328; 25189999;
D000077209	Decitabine	[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of SFN mRNA	22534328
D000077209	Decitabine	Decitabine results in decreased methylation of SFN promoter	15979784
D000077209	Decitabine	Decitabine results in increased expression of SFN mRNA	15979784
C028009	diallyl disulfide	[Cadmium Chloride co-treated with diallyl disulfide] results in decreased expression of SFN mRNA	31077537
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of SFN mRNA	21266533
D004008	Diclofenac	Diclofenac results in increased expression of SFN mRNA	17379860
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of SFN protein	31163220
D004052	Diethylnitrosamine	[3,4,5,3',4'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylnitrosamine] results in increased expression of SFN protein	23457121
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of SFN mRNA	15171707; 16636312;
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in increased expression of SFN mRNA	17547211
C516138	dorsomorphin	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
D004317	Doxorubicin	Doxorubicin results in decreased expression of SFN mRNA	24816189
D004317	Doxorubicin	Doxorubicin results in increased expression of SFN protein	24816189
D004317	Doxorubicin	SFN protein affects the susceptibility to Doxorubicin	26894857
D004317	Doxorubicin	TP53 protein mutant form affects the reaction [Doxorubicin results in decreased expression of SFN mRNA]	24816189
D004317	Doxorubicin	TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of SFN protein]	24816189
D004726	Endosulfan	Endosulfan results in increased expression of SFN mRNA	29391264
C118739	entinostat	entinostat results in increased expression of SFN mRNA	27188386
D004958	Estradiol	[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of SFN mRNA	22534328
D004958	Estradiol	[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein	22534328
D004958	Estradiol	Estradiol results in decreased expression of SFN mRNA	23019147; 23094148;
D004958	Estradiol	Estradiol results in increased expression of SFN mRNA	19167446
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in increased expression of SFN mRNA	18556351
D000431	Ethanol	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of SFN mRNA	17555576; 17942748;
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SFN mRNA	17942748
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of SFN mRNA	23649840
D005047	Etoposide	Etoposide results in increased expression of SFN mRNA	21527772
D005472	Fluorouracil	Fluorouracil affects the expression of SFN mRNA	16584549
D005472	Fluorouracil	Fluorouracil results in increased expression of SFN mRNA	16557594; 17982676;
D005472	Fluorouracil	SFN protein affects the susceptibility to [Fluorouracil co-treated with Cisplatin]	15999354
D005472	Fluorouracil	TP53 protein affects the reaction [Fluorouracil results in increased expression of SFN mRNA]	15016801
D005472	Fluorouracil	TP53 protein promotes the reaction [Fluorouracil results in increased expression of SFN mRNA]	17982676
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SFN mRNA	20938992
D005557	Formaldehyde	Formaldehyde results in increased expression of SFN mRNA	23649840
D005742	Gasoline	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D005742	Gasoline	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D005742	Gasoline	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D000077156	Gefitinib	Gefitinib results in decreased expression of SFN mRNA	16685379
C056507	gemcitabine	[DNMT1 protein binds to SFN promoter] inhibits the reaction [gemcitabine results in decreased susceptibility to gemcitabine]	25189999
C056507	gemcitabine	[gemcitabine results in decreased susceptibility to gemcitabine] inhibits the reaction [DNMT1 protein binds to SFN promoter]	25189999
C056507	gemcitabine	[gemcitabine results in decreased susceptibility to gemcitabine] which results in decreased methylation of SFN gene	25189999
C056507	gemcitabine	[gemcitabine results in decreased susceptibility to gemcitabine] which results in increased expression of SFN mRNA	25189999
C056507	gemcitabine	[gemcitabine results in decreased susceptibility to gemcitabine] which results in increased expression of SFN protein	25189999
C056507	gemcitabine	gemcitabine results in increased methylation of SFN gene	25189999
C056507	gemcitabine	SFN protein affects the reaction [YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to gemcitabine]]	26894857
C056507	gemcitabine	SFN protein affects the susceptibility to gemcitabine	26894857
C056507	gemcitabine	SFN protein inhibits the reaction [gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]	26894857
C056507	gemcitabine	SFN protein inhibits the reaction [gemcitabine results in increased cleavage of PARP1 protein]	26894857
C056507	gemcitabine	SFN protein promotes the reaction [gemcitabine results in decreased susceptibility to gemcitabine]	25189999
C056507	gemcitabine	SFN protein results in decreased susceptibility to gemcitabine	25189999; 26894857;
C056507	gemcitabine	[UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [gemcitabine results in decreased susceptibility to gemcitabine]	25189999
C056507	gemcitabine	YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to gemcitabine]	26894857
D005947	Glucose	[INS protein co-treated with Glucose] results in decreased expression of SFN mRNA	22634610
D007052	Ibuprofen	Ibuprofen results in increased expression of SFN mRNA	25596134
D007069	Ifosfamide	Ifosfamide results in increased expression of SFN mRNA	25596134
D000077146	Irinotecan	[Irinotecan co-treated with Bortezomib] results in decreased expression of SFN protein	16373703
C040507	isobutyl alcohol	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D007538	Isoniazid	Isoniazid results in decreased expression of SFN mRNA	30008028
D007545	Isoproterenol	Isoproterenol results in decreased expression of SFN mRNA	24286936
C544151	jinfukang	Cisplatin promotes the reaction [jinfukang results in increased expression of SFN mRNA]	27392435
C544151	jinfukang	jinfukang promotes the reaction [Cisplatin results in increased expression of SFN mRNA]	27392435
C544151	jinfukang	jinfukang results in increased expression of SFN mRNA	27392435
C410337	K 7174	K 7174 results in increased expression of SFN mRNA	24086573
C006552	kaempferol	kaempferol results in increased expression of SFN mRNA	18331776
C006552	kaempferol	kaempferol results in increased expression of SFN protein	18331776
C008261	lead acetate	lead acetate results in decreased expression of SFN mRNA	20680508
C533894	LG 100815	LG 100815 results in decreased expression of SFN mRNA	16951191
D047311	Luteolin	Luteolin results in increased expression of SFN mRNA	18331776
D047311	Luteolin	Luteolin results in increased expression of SFN protein	18331776
D017258	Medroxyprogesterone Acetate	[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with Decitabine] results in increased expression of SFN mRNA	22534328
D017258	Medroxyprogesterone Acetate	[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein	22534328
C042720	mercuric bromide	mercuric bromide results in increased expression of SFN mRNA	26272509
C042720	mercuric bromide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
D008687	Metformin	Metformin results in increased expression of SFN mRNA	25596134
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SFN mRNA	20938992
D008727	Methotrexate	Methotrexate results in increased expression of SFN mRNA	17379860; 21678067;
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of SFN mRNA	28001369
D008767	Methylmercury Compounds	Methylmercury Compounds results in decreased expression of SFN protein	26558463
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of SFN mRNA	21527772; 23649840;
D008942	Mitoxantrone	SFN protein affects the susceptibility to Mitoxantrone	16217747
C000622638	MLN7243	MLN7243 results in decreased sumoylation of SFN protein	31285264
D009151	Mustard Gas	Mustard Gas results in increased alkylation of SFN protein	18342354
D037742	Nanotubes, Carbon	Nanotubes, Carbon affects the expression of SFN protein	22001959
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in increased expression of SFN mRNA	25554681
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in increased expression of SFN mRNA	25554681
C031721	naphthalene	naphthalene results in increased expression of SFN mRNA	18978301
D009532	Nickel	Nickel results in increased expression of SFN mRNA	25583101
C029938	nickel sulfate	nickel sulfate results in increased expression of SFN mRNA	16100012; 16166746;
C044387	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of SFN mRNA	18778698
C044387	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	TP53 mutant form inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of SFN mRNA]	18778698
C064976	O(6)-benzylguanine	[O(6)-benzylguanine co-treated with O-(6)-methylguanine] results in decreased expression of SFN mRNA	29666243
C008449	O-(6)-methylguanine	[O(6)-benzylguanine co-treated with O-(6)-methylguanine] results in decreased expression of SFN mRNA	29666243
C464660	obeticholic acid	obeticholic acid results in decreased expression of SFN mRNA	27939613
C025589	ochratoxin A	ochratoxin A results in decreased expression of SFN mRNA	30008028; 30559759;
C025589	ochratoxin A	ochratoxin A results in increased expression of SFN mRNA	19237604
C062198	octa-2,4,6-trienoic acid	octa-2,4,6-trienoic acid results in decreased expression of SFN mRNA	16951191
D010100	Oxygen	Oxygen deficiency results in increased expression of SFN mRNA	25596134
D010100	Oxygen	[NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of SFN mRNA	30529165
D010126	Ozone	[NOTCH3 gene mutant form affects the susceptibility to Ozone] which results in increased expression of SFN mRNA	25658374
D010126	Ozone	Ozone results in increased expression of SFN mRNA	12763052; 17095637;
D000077767	Panobinostat	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
D000077767	Panobinostat	Panobinostat results in increased expression of SFN mRNA	26272509
D052638	Particulate Matter	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D052638	Particulate Matter	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D052638	Particulate Matter	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D020245	p-Chloromercuribenzoic Acid	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in increased expression of SFN mRNA	26272509
C568608	PCI 5002	[PCI 5002 co-treated with Zinc] results in increased expression of SFN mRNA	18593933
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of SFN mRNA	26272509
C006253	pirinixic acid	pirinixic acid results in decreased expression of SFN mRNA	17426115
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SFN mRNA	29432896
C019536	potassium bromate	potassium bromate results in increased expression of SFN mRNA	30008028; 30559759;
D011374	Progesterone	Progesterone results in increased expression of SFN mRNA	20631399
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in increased expression of SFN mRNA	18556351
D011374	Progesterone	Progesterone results in decreased expression of SFN mRNA	16966611
D011374	Progesterone	Progesterone results in increased phosphorylation of SFN protein	17303654
D011794	Quercetin	Quercetin results in increased expression of SFN mRNA	18331776; 21632981;
D011794	Quercetin	Quercetin results in increased expression of SFN protein	14750173; 18331776;
D012834	Silver	Silver results in increased expression of SFN mRNA	27131904
C017947	sodium arsenite	sodium arsenite results in decreased expression of SFN mRNA	12760830
C017947	sodium arsenite	sodium arsenite results in increased expression of SFN mRNA	29301061
D012969	Sodium Fluoride	Sodium Fluoride results in increased expression of SFN protein	27548804
D053260	Soot	Soot results in increased expression of SFN mRNA	26551751
C016766	sulforafan	SFN protein binds to sulforafan	21838287
D013629	Tamoxifen	Tamoxifen results in increased expression of SFN mRNA	17555576
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SFN mRNA	27913140
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SFN mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of SFN mRNA	21354282
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SFN mRNA	19770486
C009438	tetrandrine	tetrandrine results in increased expression of SFN protein	26822499
C009495	titanium dioxide	titanium dioxide results in increased expression of SFN mRNA	23409001; 27760801;
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of SFN protein	30291989
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of SFN protein	27818348
D014118	Toxins, Biological	Toxins, Biological affects the expression of SFN mRNA	19682533
C496197	trans-10,cis-12-conjugated linoleic acid	trans-10,cis-12-conjugated linoleic acid results in increased expression of SFN mRNA	17951470
D014212	Tretinoin	[bis(4-hydroxyphenyl)sulfone co-treated with Tretinoin] results in decreased expression of SFN mRNA	30951980
D014212	Tretinoin	[bisphenol A co-treated with Tretinoin] results in decreased expression of SFN mRNA	30951980
D014212	Tretinoin	[bisphenol F co-treated with Tretinoin] results in decreased expression of SFN mRNA	30951980
C011559	tributyltin	tributyltin results in decreased expression of SFN mRNA	29505797
C012589	trichostatin A	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
C012589	trichostatin A	trichostatin A results in increased expression of SFN mRNA	24935251; 26272509;
C001899	triptolide	triptolide results in increased expression of SFN protein	26990902
D014520	Urethane	Urethane results in decreased expression of SFN mRNA	28818685
D014635	Valproic Acid	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of SFN mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of SFN mRNA	23179753; 24383497; 24935251; 26272509; 27188386; 28001369; 29154799; 30008028;
D000077337	Vorinostat	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFN mRNA	27188386
D015032	Zinc	[PCI 5002 co-treated with Zinc] results in increased expression of SFN mRNA	18593933

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0025	Alternative splicing
KW-0963	Cytoplasm
KW-0903	Direct protein sequencing
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0964	Secreted
KW-0832	Ubl conjugation

Interpro

InterPro ID	InterPro Term
IPR000308	14-3-3
IPR023409	14-3-3_CS
IPR036815	14-3-3_dom_sf
IPR023410	14-3-3_domain
IPR037435	14-3-3_sigma

PROSITE

PROSITE ID	PROSITE Term
PS00796	1433_1
PS00797	1433_2

Pfam

Pfam ID	Pfam Term
PF00244	14-3-3

Gene: SFN

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction